



# Creating anti-infective opportunities

“Patients are at the heart  
of what we do”

INVESTOR PRESENTATION

September 24, 2024



# Introducing Basilea and the executive management team

- Founded in 2000 as a spin off from Roche
- Profitable Swiss commercial-stage biopharmaceutical company
- Approx. 160 employees
- Headquarters in Allschwil, Switzerland, in the Basel area life sciences hub
- Listed on the SIX Swiss Stock Exchange, Ticker: BSLN.SW



**DAVID VEITCH**  
CEO

**ADESH KAUL**  
CFO

**MARC ENGELHARDT**  
MD, PH.D CMO

**GERRIT HAUCK**  
PH.D. CTO

**LAURENZ  
KELLENBERGER**  
PH.D. CSO

JOINED 2014

2009

2010

2018

2000

PREVIOUS  
ROLES



**"Our experienced team brings deep expertise across Basilea's entire value chain."**

# Our focus is on identifying and generating commercial opportunities in the anti-infectives area

- We are focused on developing treatments for **severe bacterial and fungal diseases**
- Unmet medical needs:
  - Therapies with limited spectrum of activity
  - Growing resistance
  - Lack of oral dosing forms
  - Toxicities
- We strive to create sustainable value with meaningful benefits for patients and healthcare systems, generating long-term returns for investors and our partners
- Currently two revenue generating hospital anti-infective brands: Cresemba<sup>®</sup> and Zevtera<sup>®</sup>




## Manifestations of severe infections

<i>Candida spp.</i>	Bloodstream, abdominal, osteoarticular, cardiac, ocular, CNS, pulmonary
<i>Aspergillus spp.</i>	Pulmonary, sinuorbital, CNS, cardiac, cutaneous, abdominal
<i>Fusarium spp.</i>	Bloodstream, cutaneous, sinuorbital, ocular, CNS, pulmonary
<b>Mucorales fungi</b>	Pulmonary, sinuorbital, CNS, renal, cutaneous, abdominal
<b>Staphylococci</b>	Bloodstream, cutaneous, cardiac, abdominal, osteoarticular, pulmonary
<b>Enterobacteriaceae</b>	Bloodstream, urinary, pulmonary, cutaneous, abdominal, osteoarticular

# Business model

Unique capabilities, limited acquisition and development costs, commercialization partnerships supporting profitability



# Healthcare systems are spending > USD 20bn for hospital antifungals and antibiotics

## GLOBAL SYSTEMIC HOSPITAL ANTIFUNGALS MARKET 2023

The hospital antifungal market is valued at

USD

4.4

billion

## GLOBAL SYSTEMIC HOSPITAL ANTIBIOTICS MARKET 2023

The hospital antibiotics market is valued at

USD

17.8

billion

Source: The Lancet Infectious Diseases, Global incidence and mortality of severe fungal disease, [https://doi.org/10.1016/S1473-3099\(23\)00692-8](https://doi.org/10.1016/S1473-3099(23)00692-8)

Source: The Lancet, Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019, [https://doi.org/10.1016/S0140-6736\(22\)02185-7](https://doi.org/10.1016/S0140-6736(22)02185-7)

# Invasive fungal and severe bacterial infections are on the rise due to several factors




**Aging population** (e.g. elderly individuals more prone to infections)



**Growing population of immunocompromised individuals** (e.g. patients with chronic conditions)



Advances in **medical procedures** (e.g. medical devices like catheters or other foreign body materials)



Increased use of **immunosuppressive therapies** (e.g. for organ or stem cell transplants, **cancer therapies**, **biologic agents**)



**Agriculture: widespread use of fungicides in agriculture**




Increasing **resistance** against currently used antibiotics and antifungals



**Climate change** (e.g. growing incidence of fungal infections)

# Commercially successful hospital antifungals have achieved peak sales of ~ 600-900 USD mn



- Sales of branded antifungals typically peak around the time of their loss of exclusivity (more than 10 years market opportunity)
- Basilea’s Cresemba is already today achieving approximately USD 500 mn annual sales with continued strong double-digit year on year growth

Pfizer Inc., 2010 Financial Report, page 25  
 Merck & Co., Inc., Commission File No. 1-6571, page 124

Merck & Co., Inc., Commission File No. 1-6571, page 43  
 Astellas Pharma Inc., IFRS, Financial results for the fiscal year 2017 (FY2017), page 6

# CDC's antimicrobial resistance threats in the US

## Basilea's pipeline provides treatment options across all 3 threat levels

### Urgent Threats

These germs are public health threats that require urgent and aggressive action:

Carbapenem-resistant  
***Acinetobacter***

***Candida auris***

***Clostridioides difficile***

Carbapenem-resistant  
**Enterobacteriaceae**

Drug-resistant  
***Neisseria gonorrhoeae***

### Serious Threats

These germs are public health threats that require prompt and sustained action:

Drug-resistant  
***Campylobacter***

Drug-resistant  
***Candida***

ESBL-producing  
**Enterobacteriaceae**

Vancomycin-resistant  
**Enterococci**

Multidrug-resistant  
***Pseudomonas aeruginosa***

Drug-resistant  
***Nontyphoidal salmonella***

Drug-resistant  
***Shigella***

Methicillin-resistant  
***Staphylococcus aureus***

Drug-resistant  
***Streptococcus pneumoniae***

Drug-resistant  
**Tuberculosis**

### Concerning Threats

These germs are public health threats that require careful monitoring and prevention action:

Erythromycin-resistant  
***Group A streptococcus***

Clindamycin-resistant  
***Group B streptococcus***

### Watch list

Azole-resistant  
***Aspergillus fumigatus***

Drug-resistant  
***Mycoplasma genitalium***

Drug-resistant  
***Bordetella pertussis***

Visualized based on CDC Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. [www.cdc.gov/DrugResistance/Biggest-Threats.html](http://www.cdc.gov/DrugResistance/Biggest-Threats.html) (electronic version)



# Innovative anti-infective pipeline

Products / Product candidates / Indications	Preclinical	Phase 1	Phase 2	Phase 3	Market
<b>ANTIFUNGALS</b>					
<b>Cresemba® isavuconazole</b> Invasive aspergillosis and mucormycosis (US, EU and several other countries) <sup>1</sup> Aspergillosis, (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan)					
<b>Fosmanogepix</b> Candidemia / invasive candidiasis (including <i>Candida auris</i> ) Invasive mold infections (including invasive aspergillosis, fusariosis, Scedoporium and Lomentospora, mucormycosis and other rare mold infections)					
<b>BAL2062</b> Invasive aspergillosis					
<b>ANTIBACTERIALS</b>					
<b>Zevtera® ceftobiprole</b> Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries) <i>Staphylococcus aureus</i> bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) (US)					
<b>Tonabacase</b> Severe staphylococcal infections					
<b>LptA inhibitor</b> Severe Enterobacteriaceae infections					
<b>Internal research</b>					
<b>Focus for in-licensing and acquisitions</b>					

<sup>1</sup> The registration status and approved indications may vary from country to country.

# Non-dilutive R&D funding

## BARDA Other Transaction Agreement (OTA)

- Entered into in September 2024<sup>1</sup>
- Flexible contracting mechanism to foster innovation, promote collaboration and enable faster development timelines
- Initial commitment of USD 29 million for development of antifungals fosmanogepix and BAL2062
- Potential total funding of up to ~USD 268 million
- Reimbursement of about 60% of the total costs for the development of designated first-in-class antifungals and antibacterials in Basilea's portfolio over the term of the agreement (12 years)
- BARDA and Basilea can jointly decide to move drug candidates into and out of the portfolio

## CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)

- Funding agreement since April 2024 for LptA inhibitor program (antibiotic)<sup>2</sup>
- Initial funding of up to USD 0.9 million supports the work until candidate nomination
- Potential additional funding to continue preclinical and early clinical development of the antibiotics program if the project achieves certain milestones

<sup>1</sup> OTA number 75A50124C00033

<sup>2</sup> Agreement number 75A50122C00028 and WT224842

Anti-infective pipeline

# Antifungals











# Cresemba — Differentiated by spectrum, safety and tolerability

- Broad spectrum of activity against molds, including emerging molds (Mucorales fungi)
- Consistent plasma levels
- Statistically fewer drug-related adverse events and treatment-emergent adverse events (liver, skin, eye) in invasive aspergillosis patients vs. voriconazole in SECURE phase 3 study
- Can be administered without restriction in patients with renal impairment
- Manageable drug-drug interaction profile
- Once daily maintenance dose, IV/oral treatment
- ECIL-6 guideline: Cresemba® recommended for the first-line treatment of invasive aspergillosis in leukemia and hematopoietic stem cell transplant patients. ECIL states that isavuconazole is as effective as voriconazole with a better safety profile.

# Cresemba®

## Global commercial partnership


Marketed in  
**73**  
countries

United States	
Canada	
Latin America	
Europe (excluding Nordics)	
Nordics	
MENA Region	
Asia-Pacific and China	
Japan	

## In-market sales

USD  
**489** mn

in-market sales in the 12 months to March 2024



MAT: Moving annual total; Source: IQVIA Analytics Link, March 2024  
Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution

# Global sales of best-in-class antifungals\* by product

USD 2.9 bn sales (MAT Q1 2024)

Significant potential to increase Cresemba® (isavuconazole) global market share


- Pediatric label extension in US granted in December 2023; market exclusivity extended to September 2027
- Pediatric label extension in EU granted in August 2024; market exclusivity extended to October 2027

\* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, Liposomal Amp B, anidulafungin, caspofungin, micafungin, rezafungin



MAT: Moving annual total; Source: IQVIA Analytics Link, March 2024, rounding consistently applied


# Cresemba – the market leader in the US in terms of value



- Consistently increased market share among best-in-class antifungals\* since launch to 41% by March 2024\*\*

\* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, Liposomal Amp B, anidulafungin, caspofungin, micafungin, rezafungin

# Significant global growth potential



- USD 2.9 bn sales of best-in-class antifungals\* (MAT Q1 2024)
- Recently launched in Japan and China, representing 23% of global potential

\*\*Market share based on MAT Q1 2024, in-market sales reported as moving annual total (MAT) in US dollar; rounding consistently applied. Source: IQVIA Analytics Link, March 2024



# Fosmanogepix – Our next potential key product and mid-term value driver

- First-in-class, intravenous and oral antifungal with a novel mechanism of action
- Broad spectrum antifungal activity against yeasts, molds and dimorphic fungi, including *Candida auris*, azole-resistant *Aspergillus* spp. and *Fusarium* spp.
- Three successfully completed phase 2 studies for the treatment of
  - Candidemia, including *Candida auris*
  - Mold infections
- Phase 3-ready for yeast and mold infections
- Potential to become our next leading commercial product and mid-term value driver
- Asset acquired from Pfizer, which maintains the right of first negotiation for commercialization



# Fosmanogepix – Overview

- Fosmanogepix is the prodrug of manogepix
- Novel mechanism of action
- Inhibition of the protein Gwt1 impedes the production of cell wall mannoproteins, causing cell wall fragility, fungal cell death and decreased potential for biofilm formation
- Potent broad-spectrum activity against resistant yeasts, molds and dimorphic fungi, including azole-resistant phenotypes
- IV and oral availability enables treatment in both inpatient and outpatient settings
- US FDA fast track status, QIDP and orphan drug designations




# Fosmanogepix – Addressing high unmet medical needs

- Fast track status by the US FDA for invasive candidiasis, invasive aspergillosis, scedosporiosis, fusariosis, mucormycosis, cryptococcosis, and coccidioidomycosis
- Addressing emerging resistance issues in yeast infections including *Candida auris* and azole resistant *Aspergillus* spp.
- Potent activity against mold infections including difficult-to-treat *Fusarium* and *Scedosporium* spp.
- Wide tissue distribution enabling treatment of disseminated infections including CNS
- Favorable drug-drug interaction profile
- *In-vivo* synergism with liposomal amphotericin B and echinocandins may provide utility for the most difficult-to-treat infections

Hoenigl M, Sprute R, Egger M, et al. *Drugs*. 2021;81:1703-1729.  
Winston DJ, Young PA, Schlamm HT, Schiller GJ. *Clin Infect Dis*. 2023:ciad309.  
Gebremariam T, Gu Y, Alkhazraji S, et al. *Antimicrob Agents Chemother*. 2022;66:e0038022.

# Fosmanogepix – Potent broad-spectrum activity



\* including *C. albicans*, *C. auris*, *C. dubliniensis*, *C. glabrata*, *C. krusei*, *C. lusitaniae*, *C. parapsilosis*, *C. tropicalis*. Fosmanogepix not active against *C. krusei*.

† including *A. calidoustus*, *A. fumigatus* (including azole-resistant), *A. flavus*, *A. lentulus*, *A. nidulans*, *A. niger*, *A. terreus*, *A. tubingensis*.

‡ including *Cunninghamella spp.*, *Lichtheimia spp.*, *Mucor spp.*, *Rhizopus spp.*

§ including *Blastomyces dermatitidis*, *Coccidioides immitis*, *Histoplasma capsulatum*.

|| including *Alternaria alternata*, *Cladosporium spp.*, *Paecilomyces variotii*, *Purpureocillium lilacinum*, *Scopulariopsis spp.*, *Rasamsonia spp.*

¶ including *Trichosporon asahii*, *Exophiala dermatitidis*, *Malassezia furfur*.

Adapted from Hoenigl M, Sprute R, Egger M et al. *Drugs*. 2021;81:1703-1729.

# Fosmanogepix – Global phase 3 program

## Candidemia / Invasive candidiasis

---

- Randomized, double-blind, non-inferiority study
  - Approximately 450 patients
- Fosmanogepix IV (oral step-down fosmanogepix) vs caspofungin IV (oral step-down to fluconazole)
- Primary endpoints
  - FDA: Survival at 30 days
  - EMA: Overall response at end-of-study treatment
- Protocol and initial Health Authority approvals obtained
- Study initiated September 2024

## Invasive mold infections (IMI)

---

- Randomized, open-label study including non-controlled salvage treatment arm
  - Approximately 200 patients
- Cohorts of invasive mold disease including IMI caused by:
  - *Aspergillus* spp.
  - *Fusarium* spp.
  - *Scedosporium* spp.
  - *Lomentospora prolificans*
  - Mucorales fungi, or
  - Other multi-drug resistant molds
- Fosmanogepix IV or oral vs best available therapy
- Endpoints include survival and overall response
- Expected study start around year-end 2024

# BAL2062 – For the treatment of invasive aspergillosis

## PLACE IN THERAPY

First-line IV treatment of invasive aspergillosis (incl. azole-resistant) with the potential to deliver superior efficacy to standard-of-care

## KEY ATTRIBUTES

- New mode of action
- No cross-resistance
- Rapidly fungicidal
- Synergy with other antifungals
- Potential for superior efficacy
- No DDIs expected

## NEXT STEPS

Preclinical profiling studies ongoing. Start clinical phase 2 program in 2025

Anti-infective pipeline

# Antibacterials



# Zevtera<sup>®</sup> — An introduction

- Broad-spectrum hospital anti-MRSA cephalosporin (including Gram-negative bacteria)
  - Rapid bactericidal activity
  - Potential to replace antibiotic combinations
  - Efficacy demonstrated in phase 3 clinical studies in SAB, ABSSSI and pneumonia<sup>1, 2, 3</sup>
  - Low propensity for resistance development<sup>1</sup>
  - Safety profile consistent with the cephalosporin class safety profile, demonstrated in both adult and pediatric patients<sup>1, 2, 3, 4</sup>
- Marketed in selected countries in Europe, Latin America, the MENA-region and Canada
- US FDA approval in April 2024




Approved in major European countries & several non-European countries for both hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated pneumonia (VAP), and community-acquired bacterial pneumonia (CABP). Indicated in the US for the treatment of adult patients with *Staphylococcus aureus* bloodstream infections (bacteremia) (SAB), including right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 months old) with community-acquired bacterial pneumonia (CABP).


<sup>1</sup> Syed YY. *Drugs*. 2014;74:1523-1542 and Basilea data on file.  
<sup>2</sup> Overcash JS et al. *Clin Infect Dis*. 2021;73:e1507-e1517.  
<sup>3</sup> Holland TL et al. *N Engl J Med* 2023;389:1390-1401.  
<sup>4</sup> Rubino CM et al. *Pediatr Infect Dis J*. 2021;40:997-1003.

# Hospital anti-MRSA antibiotics; US being the most important commercial region

Daptomycin sales by region  
(2015, before LOE)



Ceftaroline sales by region  
(MAT Q1 2024)



MRSA: Methicillin-resistant *Staphylococcus aureus*; LOE: Loss of exclusivity; ROW: Rest Of World; MAT: Moving annual total; Source: IQVIA Analytics Link, March 2024



# Zevtera — Strategy for accessing the US market

FDA approved three indications April 3, 2024:

1 *Staphylococcus aureus* bacteremia (SAB)<sup>1</sup>, including right-sided endocarditis

2 Acute bacterial skin and skin structure infections (ABSSSI)<sup>2</sup>

3 Community-acquired bacterial pneumonia (CABP, adult and pediatric)<sup>3</sup>



- Phase 3 program largely funded by BARDA (~USD 112 million, or approximately 75 percent of the costs related to the SAB and ABSSSI phase 3 studies, regulatory activities and non-clinical work)<sup>4</sup>
- Qualified Infectious Disease Product (QIDP) designation extends US market exclusivity to 10 years from approval
- Commercialization planned through partnership
  - Partnering negotiations ongoing



<sup>1</sup> Holland TL et al. N Engl J Med 2023;389:1390-1401.

<sup>2</sup> Overcash JS et al. Clin Infect Dis. 2021;73:e1507-e1517.

<sup>3</sup> Nicholson SC et al. International Journal of Antimicrobial Agents 2012 (39), 240-246

<sup>4</sup> Contract number HHSO100201600002C

# Zevtera — Place in therapy

- Excellent treatment option in difficult-to-treat patients presenting to the hospital with severe infections, especially when the clinician suspects involvement of Gram-positive pathogens including *Staphylococcus aureus*
- Single agent first-line bactericidal broad-spectrum therapy with proven efficacy in SAB, ABSSSI and CABP, enabling to treat these vulnerable patients effectively early in their disease to achieve recovery
- Ceftobiprole is differentiated versus competitors in various clinically important aspects, including:
  - The strong, bactericidal activity against MSSA and MRSA
  - A robust Gram-negative coverage
  - Efficacy demonstrated in pulmonary infections in phase 3 studies
  - The safety profile reflecting the cephalosporin class
  - The low propensity for resistance development

# Tonabacase – For superior outcomes in staphylococcal infections

## PLACE IN THERAPY

Adjunct therapy to standard-of-care antibiotics in complicated staphylococcal infections, including infective endocarditis

## KEY ATTRIBUTES

- New mode of action
- Highly potent
- Rapidly bactericidal
- Active in biofilms
- Low risk of resistance development

## NEXT STEPS

Preclinical profiling studies ongoing. Decision on definitive licensing option (around year-end 2024)

# LptA inhibitors – Next generation first-in-class antibacterials

## PLACE IN THERAPY

New treatment option for the most frequent Gram-negative pathogens causing bloodstream infections (Enterobacteriaceae), including carbapenem-resistant isolates

## KEY ATTRIBUTES

- New mode of action
- Bactericidal
- Highly potent
- No cross-resistance to other antibiotic classes

## NEXT STEPS

Start first-in-human studies in 2026



# Financials & Outlook

## Financial report

### Financial review

#### Overview

The following discussion of the financial condition and results of the operations of Basilea Pharmaceutica Ltd, Albstadt ("Basilea") and its subsidiaries (the "Company") should be read in conjunction with the consolidated financial statements, which have been prepared in accordance with US GAAP, and the related notes thereto included in this annual report. This discussion contains forward-looking statements which are based on assumptions about the Company's future business that involve risks and uncertainties. The Company's actual results may differ materially from those anticipated in these forward-looking statements.

Basilea through its operating company Basilea Pharmaceutica International Ltd, Albstadt ("Basilea International"), is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections.

The Company recognized total revenue of CHF 157.6 million in 2022 (2021: CHF 147.8 million). Total revenue in 2022 included CHF 155.5 million (2021: CHF 122.3 million) from Basilea's two marketed products, the antifungal Caspexin (caspofungin) and the antibiotic Zevtera (ceftazidime). Moreover, total revenue included other revenue in the amount of CHF 2.1 million (2021: CHF 25.4 million).

In 2022, the Company invested CHF 77.9 million (2021: CHF 71.9 million) in research and development projects in the Company's research portfolio as well as commercial and financial projects for the expansion of its R&D portfolio aimed at optimizing and accelerating commercialization and R&D efforts, and through the execution of the strategic partnership with S&L (S&L) and the exclusive license agreement for the antibiotic, Zevtera.

Selling, general and administrative expenses including costs for the commercialization of Caspexin and Zevtera amounted to CHF 128.6 million in 2022 (2021: CHF 101.8 million).

Contract revenue and contract revenue related to the sale of products sold amounted to CHF 122.3 million as of December 31, 2022. The Company also recognized CHF 23.4 million of contract revenue related to the sale of products sold in 2022, which CHF 26.8 million was primarily generated with a new stock purchase of CHF 20.0 million in 2022, which CHF 26.8 million was already paid back as of December 31, 2022.

#### Results of operations

The following table outlines the Company's consolidated results of operations for the periods ended 2022 and 2021.

	2022	2021
Product revenue	155.5	122.3
Contract revenue	2.1	25.4
Other revenue	157.6	147.8
Cost of products sold	(26.8)	(24.6)
Research & development expenses	(77.9)	(71.9)
Selling, general & administrative expenses	(128.6)	(101.8)
Total cost and operating expense	(233.3)	(198.3)
Operating income	19.2	18.5
Interest expense	(1.2)	(0.3)
Other income	2.4	2.9
Other components of the periodic pension cost	(4.6)	(1.2)
Income taxes	2.1	2.1
Net profit	0.0	9.9
	10.5	12.1

Total revenue included product revenue in the amount of CHF 155.5 million (2021: CHF 122.3 million) and contract revenue in the amount of CHF 2.1 million (2021: CHF 25.4 million). Product revenue resulted from sales to Pfizer in the amount of CHF 14.1 million (2021: CHF 16.9 million) and product sales to other distribution and license partners of CHF 21.9 million (2021: CHF 15.5 million).

Contract revenue resulted from royalty payments from Anasofa of CHF 51.1 million (2021: CHF 42.8 million) royalty payments and a sales milestone payment of CHF 20.0 million. Furthermore, the Company recognized contract revenue from Pfizer of CHF 21.4 million (2021: CHF 23.4 million), including royalty payments of CHF 27.4 million (2021: CHF 22.2 million) and sales milestone payments of CHF 26.7 million (2021: CHF 15.0 million).

In other revenue, the Company recognized CHF 4.2 million related to its agreement with BARDA (2021: CHF 8.4 million) and CHF 0.0 million related to licensing transactions (2021: CHF 15.0 million).

Cost of products sold


The Company recognized cost of products sold of CHF 26.8 million for Caspexin and Zevtera (2021: CHF 24.6 million).

# Strong financial results H1 2024 – Cresemba royalty growth, sustained profits and positive cash flow

In CHF million	H1 2024	H1 2023	2023
<b>Cresemba and Zevtera related revenue</b>	<b>73.3</b>	80.5	<b>150.3</b>
of which royalty income	<b>42.8</b>	36.7	<b>78.9</b>
of which milestone payments	<b>2.9</b>	30.6	<b>32.2</b>
<b>Total revenue</b>	<b>76.3</b>	84.9	<b>157.6</b>
Cost of products sold	<b>18.1</b>	10.0	<b>26.8</b>
Operating expenses	<b>48.9</b>	38.0	<b>111.6</b>
Operating result	<b>9.3</b>	36.9	<b>19.2</b>
<b>Net profit</b>	<b>20.7</b>	31.8	<b>10.5</b>
<b>Net financial debt</b> (as of June 30, 2024/2023 and December 31, 2023)	<b>26.2</b>	38.1	<b>46.6</b>


Note: Consolidated figures in conformity with US GAAP; rounding applied consistently

# Cash flows from operating activities (in CHF mn)




Note: Consolidated figures in conformity with US GAAP; rounding applied consistently

# Continued strong growth in Cresemba and Zevtera related revenue (in CHF mn)





# CHF 124 mn reduction of debt level 2022 – H1 2024



Note: Figures in CHF mn

# Increased FY 2024 financial guidance

In CHF million	FY 2023	FY 2024 (previous guidance)	FY 2024 (current guidance)
Cresemba and Zevtera related revenue	150.3	~190	<b>~190</b>
<i>of which royalty income</i>	78.9	~92	<b>~92</b>
<b>Total revenue</b>	157.6	~196	<b>~203</b>
Cost of products sold	26.8	~40	<b>~40</b>
Operating expenses	111.6	~120	<b>~120</b>
Operating result	19.2	~36	<b>~43</b>
<b>Net profit</b>	10.5	~42	<b>~60</b>

Note: Consistent rounding was applied.

# Key milestones

	Product	H1 2024	H2 2024
Antibacterials	Ceftobiprole (Zevtera)	✓ US FDA approval	
	Tonabacase		Executing US partnership
Antifungals	Isavuconazole (Cresemba)	✓ EMA/CHMP positive opinion on pediatric indication	✓ EC decision on pediatric indication
	Fosmanogepix		✓ Initiate phase 3 study in candidemia / invasive candidiasis Initiate phase 3 study in mold infections (around year-end)

Increasing Cresemba & Zevtera revenue

In-licensing and acquisition of anti-infectives

Advancement of preclinical and clinical anti-infective assets

Non-dilutive R&D funding for anti-infectives portfolio

# Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.



# Peer Nils Schröder, PhD

Head of Corporate Communications  
& Investor Relations

Basilea Pharmaceutica International Ltd, Allschwil  
Hegenheimermattweg 167b  
4123 Allschwil | Switzerland

Phone +41 61 606 1102  
E-mail [investor\\_relations@basilea.com](mailto:investor_relations@basilea.com)

# Glossary

- ABSSSI: **A**cute **b**acterial **s**kin and **s**kin **s**tructure **i**nfections
- BARDA: **B**iomedical **A**dvanced **R**esearch and **D**evelopment **A**uthority
- CABP: **C**ommunity-**a**cquired **b**acterial **p**neumonia
- CNS **C**entral **N**ervous **S**ystem
- CARB-X: **C**ombating **A**ntibiotic-**R**esistant **B**acteria **B**iopharmaceutical **A**ccelerator
- EC: **E**uropean **C**ommission
- EMA: **E**uropean **M**edicines **A**gency
- FDA: **U**S **F**ood and **D**rug **A**dministration
- HABP: **H**ospital-**a**cquired **b**acterial **p**neumonia
- IMI: **I**nvasive **m**old infections
- IV: **I**ntravenous
- MSSA: **M**ethicillin-**s**usceptible *Staphylococcus aureus*
- MRSA: **M**ethicillin-**r**esistant *Staphylococcus aureus*
- QIDP: **Q**ualified **I**nfectious **D**isease **P**roduct
- SAB: *Staphylococcus aureus* **b**acteremia
- US GAAP: **U**nited **S**tates **G**enerally **A**ccepted **A**ccounting **P**inciples
- VAP: **V**entilator-**a**sociated **p**neumonia



**Creating anti-infective  
opportunities**

**Hegenheimermattweg 167b  
4123 Allschwil  
Switzerland**

**[info@basilea.com](mailto:info@basilea.com)  
[www.basilea.com](http://www.basilea.com)**

All rights reserved.  
© 2024 Basilea Pharmaceutica International Ltd, Allschwil